Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

EGF receptor and COX-1/COX-2 enzyme proteins as related to corresponding mRNAs in human per-operative biopsies of colorectal cancer

Authors: Annika Gustafsson Asting, Ava Farivar, Britt-Marie Iresjö, Helena Svensson, Bengt Gustavsson, Kent Lundholm

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Cyclooxygenase (COX) and epidermal growth factor receptor (EGFR) activities promote progression of colorectal cancer. Combined treatment against these targets has not been more effective than single treatments alone. Therefore, our aim was to analyze relationships between COX and EGFR in peroperative colorectal tumor biopsies.

Method

Tumor and colon mucosa tissue were collected at primary intended curative operations in patients according to well-recognized statistical distributions of tumor stages in colorectal cancer. COX-1, COX-2 and EGFR content in tumor and colon mucosa tissue were quantified by western blot and Q-PCR.

Results

COX-2 protein appeared as two bands, one at 66 kDa in almost all tumor and mucosa samples and one at 74 kDa in 73% of the tumors and in 23% of the mucosa samples. Tumor COX-2 mRNA was not different from the content in mucosa samples, while COX-2 protein was increased in tumor tissue (p < 0.0003). A correlation between 74 kDa COX-2 protein and COX-2 mRNA occurred in tumor tissue, with significantly increasing COX-2 mRNA across tumor stages. EGFR mRNA content was lower in tumor tissue (p < 0.0001), while EGFR protein was similar in tumor and mucosa samples. COX-2 and EGFR proteins showed a positive correlation in mucosa, while a negative correlation occurred in tumor tissue. Tumor tissue with high COX-2 74 kDa protein lacked EGFR protein.

Conclusion

Our present results are compatible with the theory that COX-2 and EGFR signalling pathways are inversely related in colorectal cancer tissue. This may explain why combinatorial clinical treatments have been less rewarding.
Appendix
Available only for authorised users
Literature
1.
go back to reference Thun MJ, et al: Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53 (6): 1322-1327.PubMed Thun MJ, et al: Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53 (6): 1322-1327.PubMed
2.
go back to reference Thun MJ, Namboodiri MM, Heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991, 325 (23): 1593-1596. 10.1056/NEJM199112053252301.CrossRefPubMed Thun MJ, Namboodiri MM, Heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991, 325 (23): 1593-1596. 10.1056/NEJM199112053252301.CrossRefPubMed
3.
go back to reference Sato T, et al: Cyclooxygenase-2 expression and its relationship with proliferation of colorectal adenomas. Jpn J Clin Oncol. 2003, 33 (12): 631-635. 10.1093/jjco/hyg114.CrossRefPubMed Sato T, et al: Cyclooxygenase-2 expression and its relationship with proliferation of colorectal adenomas. Jpn J Clin Oncol. 2003, 33 (12): 631-635. 10.1093/jjco/hyg114.CrossRefPubMed
4.
go back to reference Sano H, et al: Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res. 1995, 55 (17): 3785-3789.PubMed Sano H, et al: Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res. 1995, 55 (17): 3785-3789.PubMed
5.
go back to reference Greenhough A, et al: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009, 30 (3): 377-386. 10.1093/carcin/bgp014.CrossRefPubMed Greenhough A, et al: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009, 30 (3): 377-386. 10.1093/carcin/bgp014.CrossRefPubMed
6.
go back to reference Cunningham D, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351 (4): 337-345. 10.1056/NEJMoa033025.CrossRefPubMed Cunningham D, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351 (4): 337-345. 10.1056/NEJMoa033025.CrossRefPubMed
7.
go back to reference Saltz LB, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004, 22 (7): 1201-1208. 10.1200/JCO.2004.10.182.CrossRefPubMed Saltz LB, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004, 22 (7): 1201-1208. 10.1200/JCO.2004.10.182.CrossRefPubMed
8.
9.
go back to reference Buchanan FG, et al: Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007, 67 (19): 9380-9388. 10.1158/0008-5472.CAN-07-0710.CrossRefPubMed Buchanan FG, et al: Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007, 67 (19): 9380-9388. 10.1158/0008-5472.CAN-07-0710.CrossRefPubMed
10.
go back to reference Chan E, et al: Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am J Clin Oncol. 2011, 34 (6): 581-586. 10.1097/COC.0b013e3181fe46a1.CrossRefPubMedPubMedCentral Chan E, et al: Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am J Clin Oncol. 2011, 34 (6): 581-586. 10.1097/COC.0b013e3181fe46a1.CrossRefPubMedPubMedCentral
11.
go back to reference Axelsson H, et al: Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo. Int J Oncol. 2011, 37 (5): 1143-1152. Axelsson H, et al: Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo. Int J Oncol. 2011, 37 (5): 1143-1152.
12.
go back to reference Gustafsson A, et al: EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer. 2007, 121 (2): 232-240. 10.1002/ijc.22582.CrossRefPubMed Gustafsson A, et al: EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer. 2007, 121 (2): 232-240. 10.1002/ijc.22582.CrossRefPubMed
13.
go back to reference Eberhart CE, et al: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994, 107 (4): 1183-1188.CrossRefPubMed Eberhart CE, et al: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994, 107 (4): 1183-1188.CrossRefPubMed
14.
go back to reference Chapple KS, et al: Analysis of cyclooxygenase expression in human colorectal adenomas. Dis Colon Rectum. 2002, 45 (10): 1316-1324. 10.1007/s10350-004-6418-3.CrossRefPubMed Chapple KS, et al: Analysis of cyclooxygenase expression in human colorectal adenomas. Dis Colon Rectum. 2002, 45 (10): 1316-1324. 10.1007/s10350-004-6418-3.CrossRefPubMed
15.
go back to reference Hwang D, et al: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998, 90 (6): 455-460. 10.1093/jnci/90.6.455.CrossRefPubMed Hwang D, et al: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998, 90 (6): 455-460. 10.1093/jnci/90.6.455.CrossRefPubMed
16.
go back to reference Cahlin C, et al: The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol. 2005, 27 (4): 913-923.PubMed Cahlin C, et al: The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol. 2005, 27 (4): 913-923.PubMed
17.
go back to reference Lonnroth C, et al: Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 2008, 8: 5-PubMedPubMedCentral Lonnroth C, et al: Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 2008, 8: 5-PubMedPubMedCentral
18.
go back to reference Gustafsson A, et al: Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2. Int J Oncol. 2010, 36 (2): 469-478.PubMed Gustafsson A, et al: Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2. Int J Oncol. 2010, 36 (2): 469-478.PubMed
20.
go back to reference Shao J, et al: Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem. 2000, 275 (43): 33951-33956. 10.1074/jbc.M002324200.CrossRefPubMed Shao J, et al: Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem. 2000, 275 (43): 33951-33956. 10.1074/jbc.M002324200.CrossRefPubMed
21.
go back to reference Tsatsanis C, et al: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006, 38 (10): 1654-1661. 10.1016/j.biocel.2006.03.021.CrossRefPubMed Tsatsanis C, et al: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006, 38 (10): 1654-1661. 10.1016/j.biocel.2006.03.021.CrossRefPubMed
22.
go back to reference Mbonye UR, Song I: Posttranscriptional and posttranslational determinants of cyclooxygenase expression. BMB Rep. 2009, 42 (9): 552-560. 10.5483/BMBRep.2009.42.9.552.CrossRefPubMed Mbonye UR, Song I: Posttranscriptional and posttranslational determinants of cyclooxygenase expression. BMB Rep. 2009, 42 (9): 552-560. 10.5483/BMBRep.2009.42.9.552.CrossRefPubMed
23.
go back to reference Sevigny MB, et al: Glycosylation regulates turnover of cyclooxygenase-2. FEBS Lett. 2006, 580 (28–29): 6533-6536.CrossRefPubMed Sevigny MB, et al: Glycosylation regulates turnover of cyclooxygenase-2. FEBS Lett. 2006, 580 (28–29): 6533-6536.CrossRefPubMed
24.
go back to reference Singer II, et al: Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 1998, 115 (2): 297-306. 10.1016/S0016-5085(98)70196-9.CrossRefPubMed Singer II, et al: Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 1998, 115 (2): 297-306. 10.1016/S0016-5085(98)70196-9.CrossRefPubMed
25.
go back to reference Otto JC, DeWitt DL, Smith WL: N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem. 1993, 268 (24): 18234-18242.PubMed Otto JC, DeWitt DL, Smith WL: N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem. 1993, 268 (24): 18234-18242.PubMed
26.
go back to reference Crofford LJ, et al: Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues: effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest. 1994, 93 (3): 1095-1101. 10.1172/JCI117060.CrossRefPubMedPubMedCentral Crofford LJ, et al: Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues: effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest. 1994, 93 (3): 1095-1101. 10.1172/JCI117060.CrossRefPubMedPubMedCentral
27.
go back to reference Torrance CJ, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000, 6 (9): 1024-1028. 10.1038/79534.CrossRefPubMed Torrance CJ, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000, 6 (9): 1024-1028. 10.1038/79534.CrossRefPubMed
28.
go back to reference Zhang X, et al: Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res. 2005, 11 (17): 6261-6269. 10.1158/1078-0432.CCR-04-2102.CrossRefPubMed Zhang X, et al: Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res. 2005, 11 (17): 6261-6269. 10.1158/1078-0432.CCR-04-2102.CrossRefPubMed
29.
go back to reference Tortora G, et al: Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 2003, 9 (4): 1566-1572.PubMed Tortora G, et al: Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 2003, 9 (4): 1566-1572.PubMed
30.
go back to reference Antonacopoulou AG, et al: EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology. 2008, 53 (6): 698-706. 10.1111/j.1365-2559.2008.03165.x.CrossRefPubMed Antonacopoulou AG, et al: EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology. 2008, 53 (6): 698-706. 10.1111/j.1365-2559.2008.03165.x.CrossRefPubMed
31.
go back to reference Buchanan FG, et al: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003, 278 (37): 35451-35457. 10.1074/jbc.M302474200.CrossRefPubMed Buchanan FG, et al: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003, 278 (37): 35451-35457. 10.1074/jbc.M302474200.CrossRefPubMed
32.
go back to reference Wang JY, et al: Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cell Signal. 2011, 24 (1): 162-169.CrossRefPubMed Wang JY, et al: Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cell Signal. 2011, 24 (1): 162-169.CrossRefPubMed
34.
go back to reference Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5 (5): 341-354. 10.1038/nrc1609.CrossRefPubMed Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5 (5): 341-354. 10.1038/nrc1609.CrossRefPubMed
35.
go back to reference Messa C, et al: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998, 37 (3): 285-289. 10.1080/028418698429595.CrossRefPubMed Messa C, et al: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998, 37 (3): 285-289. 10.1080/028418698429595.CrossRefPubMed
36.
go back to reference Misale S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012, 486 (7404): 532-536.PubMedPubMedCentral Misale S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012, 486 (7404): 532-536.PubMedPubMedCentral
37.
go back to reference Horton HR, Moran LA, Ochs RS, Rawn JD, Scrimgeour KG: Principles of Biochemistry. Edited by: Paul C. 1996, Upper Sadle River: Prentice-Hall, Inc, 801-2 Horton HR, Moran LA, Ochs RS, Rawn JD, Scrimgeour KG: Principles of Biochemistry. Edited by: Paul C. 1996, Upper Sadle River: Prentice-Hall, Inc, 801-2
Metadata
Title
EGF receptor and COX-1/COX-2 enzyme proteins as related to corresponding mRNAs in human per-operative biopsies of colorectal cancer
Authors
Annika Gustafsson Asting
Ava Farivar
Britt-Marie Iresjö
Helena Svensson
Bengt Gustavsson
Kent Lundholm
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-511

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine